Further, since it is known that carriers of BRCA1/2 pathogenic variants who develop BC have a different prognosis and clinical outcome compared to non‐carriers,11, 48 another aspect that would be interesting to evaluate in the future is whether the c.5017_5019del (p.His1673del) variant, in addition to being associated with a different risk of breast cancer compared to other BRCA1 variants, is also associated with a different prognosis. This evidence concerns the gene BRCA1 and breast cancer.